Puma lentivirus is controlled in domestic cats after mucosal exposure in the absence of conventional indicators of immunity.
A high percentage of free-ranging pumas (Felis concolor) are infected with feline lentiviruses (puma lentivirus, feline immunodeficiency virus Pco [FIV-Pco], referred to here as PLV) without evidence of disease. PLV establishes productive infection in domestic cats following parenteral exposure but, in contrast to domestic cat FIV, it does not cause T-cell dysregulation. Here we report that cats exposed to PLV oro-nasally became infected yet rapidly cleared peripheral blood mononuclear cell (PBMC) proviral load in the absence of a correlative specific immune response. Two groups of four specific-pathogen-free cats were exposed to PLV via the mucosal (oro-nasal) or parenteral (i.v.) route. All animals were PBMC culture positive and PCR positive within 3 weeks postinfection and seroconverted without exhibiting clinical disease; however, three or four oro-nasally infected animals cleared circulating proviral DNA within 3 months. Antibody titers reached higher levels in animals that remained persistently infected. PLV antigen-induced proliferation was slightly greater in mucosally inoculated animals, but no differences were noted in cytotoxic T-lymphocyte responses or cytokine profiles between groups. The distribution of virus was predominantly gastrointestinal as opposed to lymphoid in all animals in which virus was detected at necropsy. Possible mechanisms for viral clearance include differences in viral fitness required for crossing mucosal surfaces, a threshold dose requirement for persistence, or an undetected sterilizing host immune response. This is the first report of control of a productive feline or primate lentivirus infection in postnatally exposed, seropositive animals. Mechanisms underlying this observation will provide clues to containment of immunodeficiency disease and could prompt reexamination of vaccine-induced immunity against human immunodeficiency virus and other lentiviruses.
Terwee
Julie A
JA
Department of Microbiology, Immunology and Pathology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, CO 80523-1619, USA.
Yactor
Jennifer K
JK
Sondgeroth
Kerry S
KS
Vandewoude
Sue
S
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000914:Antibodies, Viral / Q000097:blood; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002415:Cats / Q000276:immunology* / Q000821:virology*; D016207:Cytokines / Q000096:biosynthesis; D016181:Feline Acquired Immunodeficiency Syndrome / Q000276:immunology* / Q000517:prevention & control / Q000821:virology*; D005260:Female; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular; D018928:Immunity, Mucosal; D016089:Immunodeficiency Virus, Feline / Q000276:immunology* / Q000302:isolation & purification / Q000472:pathogenicity*; D008297:Male; D009928:Organ Specificity; D011533:Proviruses / Q000302:isolation & purification; D046011:Puma / Q000821:virology
D000893:Anti-Inflammatory Agents; D000914:Antibodies, Viral; D016207:Cytokines